Coronary artery bypass surgery hormonal manipulation: Difference between revisions
Jump to navigation
Jump to search
Varun Kumar (talk | contribs) mNo edit summary |
No edit summary |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Coronary artery bypass surgery}} | {{Coronary artery bypass surgery}} | ||
{{CMG | {{CMG}} | ||
==ACCF/AHA | ==2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)<ref name="pmid22064599">{{cite journal| author=Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG et al.| title=2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2011 | volume= | issue= | pages= | pmid=22064599 | doi=10.1161/CIR.0b013e31823c074e | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22064599 }} </ref>== | ||
{ | ===Coronary artery bypass surgery hormonal manipulation=== | ||
== | {|class="wikitable" | ||
'''1.''' Use of continuous intravenous insulin to achieve and maintain an early postoperative blood glucose concentration less than or equal to 180 mg/dL while avoiding [[hypoglycemia]] is indicated to reduce the incidence of adverse events, including deep sternal wound infection, after CABG | |- | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Use of continuous intravenous [[insulin]] to achieve and maintain an early postoperative blood glucose concentration less than or equal to 180 mg/dL while avoiding [[hypoglycemia]] is indicated to reduce the incidence of adverse events, including deep sternal wound infection, after CABG ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III: HARM]] | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Postmenopausalhormonaltherapy([[estrogen]]/[[prosgesterone]])shouldnot be administered to women undergoing CABG ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | {|class="wikitable" | ||
|- | |||
The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness | | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | ||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
==References== | ==References== | ||
| Line 27: | Line 33: | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
Latest revision as of 17:29, 1 November 2016
|
Coronary Artery Bypass Surgery Microchapters | |
|
Pathophysiology | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Perioperative Monitoring | |
|
Surgical Procedure | |
|
Special Scenarios | |
|
Coronary artery bypass surgery hormonal manipulation On the Web | |
|
Coronary artery bypass surgery hormonal manipulation in the news | |
|
Blogs on Coronary artery bypass surgery hormonal manipulation|- |
|
|
Directions to Hospitals Performing Coronary artery bypass surgery hormonal manipulation | |
|
Risk calculators for Coronary artery bypass surgery hormonal manipulation | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)[1]
Coronary artery bypass surgery hormonal manipulation
| Class I |
| "1. Use of continuous intravenous insulin to achieve and maintain an early postoperative blood glucose concentration less than or equal to 180 mg/dL while avoiding hypoglycemia is indicated to reduce the incidence of adverse events, including deep sternal wound infection, after CABG (Level of Evidence: B)" |
| Class III: HARM |
| "1. Postmenopausalhormonaltherapy(estrogen/prosgesterone)shouldnot be administered to women undergoing CABG (Level of Evidence: B)" |
| Class IIb |
| "1. The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness (Level of Evidence: B)" |
References
- ↑ Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.